MXCT
MAXCYTE, INC.
NASDAQ · Healthcare · Medical - Devices · US
$1.30
+0.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.29
From 52W high−26.14%
Volume985610.00
Market cap$134.17M
P/E (TTM)—
P/S (TTM)4.3x
Div yield—
Key dataOct 19, 2026
Open
$1.29
From 52W high
−26.14%
Volume
985610.00
Market cap
$134.17M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
P/E (TTM)
—
RSI (14)
63.7
MomentumView details →
1D Return
+0.00%
YTD Return
−16.13%
SummaryUpdated Jun 1, 2026
MaxCyte, Inc. (NASDAQ:MXCT) is a global life sciences company founded in 1998 and headquartered in Rockville, Maryland. The company specializes in cell engineering technology that enables the development of next-generation cell therapies. MaxCyte went public in July 2021 and has established itself as a key enabler in the emerging cell and gene therapy industry. The company's electroporation technology platform has supported the development of CASGEVY, the first FDA-approved non-viral cell therapy, and maintains partnerships with numerous biotechnology and pharmaceutical companies developing cell-based treatments.
Similar companies
Latest newsMore news →
MaxCyte raised its 2026 revenue guidance to approximately $34 million, including approximately $28 million from its core business and $6 million in SPL program-related revenue.6d agoMaxCyte reported preliminary third-quarter 2026 revenue of $9.1 million, including $8.1 million from its core business, up 26% year over year, and $1.0 million in SPL program-related revenue.6d agoMaxCyte granted inducement stock options for 220,000 shares and a restricted stock unit award for 110,000 shares to Sidharth Kapileshwar in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development Officer.38d ago